177 related articles for article (PubMed ID: 32250180)
1. Adalimumab in children and adolescents with severe plaque psoriasis: a safety evaluation.
Zangrilli A; Bavetta M; Bianchi L
Expert Opin Drug Saf; 2020 Apr; 19(4):433-438. PubMed ID: 32250180
[No Abstract] [Full Text] [Related]
2. Adalimumab: A Review in Chronic Plaque Psoriasis.
Burness CB; McKeage K
Drugs; 2015 Dec; 75(18):2119-30. PubMed ID: 26586242
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab in severe plaque psoriasis of childhood: A multi-center, retrospective real-life study up to 52 weeks observation.
Di Lernia V; Bianchi L; Guerriero C; Stingeni L; Gisondi P; Filoni A; Guarneri C; Belloni Fortina A; Lasagni C; Simonetti O; Neri I; Zangrilli A; Moretta G; Hansel K; Casanova DM; Girolomoni G; Cannavò SP; Bonamonte D
Dermatol Ther; 2019 Nov; 32(6):e13091. PubMed ID: 31579972
[TBL] [Abstract][Full Text] [Related]
4. Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study.
Thaçi D; Papp K; Marcoux D; Weibel L; Pinter A; Ghislain PD; Landells I; Hoeger PH; Unnebrink K; Seyger MMB; Williams DA; Rubant S; Philipp S
Br J Dermatol; 2019 Dec; 181(6):1177-1189. PubMed ID: 31017657
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa.
Tzanetakou V; Stergianou D; Giamarellos-Bourboulis EJ
Expert Opin Drug Saf; 2020 Apr; 19(4):381-393. PubMed ID: 32098513
[No Abstract] [Full Text] [Related]
6. Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis.
Leonardi C; Papp K; Strober B; Thaçi D; Warren RB; Tyring S; Arikan D; Karunaratne M; Valdecantos WC
Br J Dermatol; 2019 Jan; 180(1):76-85. PubMed ID: 30169904
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial.
Papp K; Thaçi D; Marcoux D; Weibel L; Philipp S; Ghislain PD; Landells I; Hoeger P; Kotkin C; Unnebrink K; Seyger M; Williams D
Lancet; 2017 Jul; 390(10089):40-49. PubMed ID: 28478975
[TBL] [Abstract][Full Text] [Related]
8. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.
Revicki D; Willian MK; Saurat JH; Papp KA; Ortonne JP; Sexton C; Camez A
Br J Dermatol; 2008 Mar; 158(3):549-57. PubMed ID: 18047521
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis.
Bongiorno MR; Pistone G; Doukaki S; Aricò M
Dermatol Ther; 2008 Oct; 21 Suppl 2():S15-20. PubMed ID: 18837728
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab for the treatment of severe psoriasis and psoriatic arthritis.
Papoutsaki M; Costanzo A; Chimenti MS; Chimenti S
Expert Opin Biol Ther; 2008 Mar; 8(3):363-70. PubMed ID: 18294106
[TBL] [Abstract][Full Text] [Related]
12. Results of a retrospective study on the efficacy and safety of adalimumab 80 mg administrated every other week in patients with psoriasis at a single Japanese institution.
Kamiya K; Karakawa M; Komine M; Kishimoto M; Sugai J; Ohtsuki M
J Dermatol; 2019 Mar; 46(3):199-205. PubMed ID: 30672612
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis.
Saraceno R; Bavetta M; Zangrilli A; Chiricozzi A; Potenza C; Chimenti S; Chimenti MS
Expert Opin Biol Ther; 2013 Sep; 13(9):1325-34. PubMed ID: 23930916
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab for treating childhood plaque psoriasis: a clinical trial evaluation.
Di Lernia V
Expert Opin Biol Ther; 2017 Dec; 17(12):1553-1556. PubMed ID: 28829204
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment of psoriatic patients with adalimumab reduces disease severity and maintains a favorable lipid pattern and a low Atherogenic Index.
Zangrilli A; Bavetta M; Scaramella M; Bianchi L
G Ital Dermatol Venereol; 2018 Apr; 153(2):146-154. PubMed ID: 29564871
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study.
Revicki DA; Menter A; Feldman S; Kimel M; Harnam N; Willian MK
Health Qual Life Outcomes; 2008 Oct; 6():75. PubMed ID: 18831744
[TBL] [Abstract][Full Text] [Related]
18. Biologic response modifiers and pediatric psoriasis.
Bellodi Schmidt F; Shah KN
Pediatr Dermatol; 2015; 32(3):303-20. PubMed ID: 25727936
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
Kimball AB; Bensimon AG; Guerin A; Yu AP; Wu EQ; Okun MM; Bao Y; Gupta SR; Mulani PM
Am J Clin Dermatol; 2011 Feb; 12(1):51-62. PubMed ID: 21110526
[TBL] [Abstract][Full Text] [Related]
20. Anti-TNF therapy-induced lupus erythematosus-like syndrome in a patient treated with adalimumab for cutaneous psoriasis.
Stein JE; Patterson-Fortin J; Bodnar BE
BMJ Case Rep; 2018 Apr; 2018():. PubMed ID: 29654101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
